Dynamics of the Cell-Free DNA Methylome of Metastatic Prostate Cancer During Androgen-Targeting Treatment

References

• Bray F , FerlayJ , SoerjomataramI , SiegelRL , TorreLA , JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.68(6), 394–424 (2018).
   PubMed Web of Science ®Google Scholar
• Global Burden of Disease Cancer C , FitzmauriceC , AllenCet al.Global, regional and national cancer incidence, mortality, years of life lost, years lived with disability and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol.3(4), 524–548 (2017).
   PubMed Web of Science ®Google Scholar
• Wong YN , FerraldeschiR , AttardG , de BonoJ. Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nat Rev. Clin. Oncol.11(6), 365–376 (2014).
   PubMed Web of Science ®Google Scholar
• Sridhar SS , FreedlandSJ , GleaveMEet al. Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur. Urol.65(2), 289–299 (2014).
   PubMed Web of Science ®Google Scholar
• Crawford ED , PetrylakD , SartorO. Navigating the evolving therapeutic landscape in advanced prostate cancer. Urol. Oncol.35S, S1–S13 (2017).
   Google Scholar
• Scher HI , FizaziK , SaadFet al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med.367(13), 1187–1197 (2012).
   PubMed Web of Science ®Google Scholar
• Loriot Y , MillerK , SternbergCNet al. Effect of enzalutamide on health-related quality of life, pain and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, Phase 3 trial. Lancet Oncol.16(5), 509–521 (2015).
   PubMed Web of Science ®Google Scholar
• de Bono JS , LogothetisCJ , MolinaAet al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med.364(21), 1995–2005 (2011).
   PubMed Web of Science ®Google Scholar
• Ryan CJ , SmithMR , FizaziKet al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol.16(2), 152–160 (2015).
   PubMed Web of Science ®Google Scholar
• Bambury RM , ScherHI. Enzalutamide: the story of its development from bench to bedside. Urol. Oncol.33(6), 280–288 (2015).
   PubMed Web of Science ®Google Scholar
• Grist E , de BonoJS , AttardG. Targeting extra-gonadal androgens in castration-resistant prostate cancer. J. Steroid Biochem. Mol. Biol.145, 157–163 (2015).
   PubMed Web of Science ®Google Scholar
• Sumanasuriya S , DeBono J. Treatment of advanced prostate cancer-a review of current therapies and future promise. Cold Spring Harb. Perspect. Med.8(6), 1–13 (2018).
   Web of Science ®Google Scholar
• Fizazi K , TranN , FeinLet al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med.377(4), 352–360 (2017).
   PubMed Web of Science ®Google Scholar
• James ND , de BonoJS , SpearsMRet al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med.377(4), 338–351 (2017).
   PubMed Web of Science ®Google Scholar
• Armstrong AJ , SzmulewitzRZ , PetrylakDPet al. ARCHES: a randomized, Phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol.37(32), 2974–2986 (2019).
   Web of Science ®Google Scholar
• Robinson D , Van AllenEM , WuYMet al. Integrative clinical genomics of advanced prostate cancer. Cell161(5), 1215–1228 (2015).
   PubMed Web of Science ®Google Scholar
• Armenia J , WankowiczSAM , LiuDet al. The long tail of oncogenic drivers in prostate cancer. Nat. Genet.50(5), 645–651 (2018).
   PubMed Web of Science ®Google Scholar
• Wyatt AW , AnnalaM , AggarwalRet al. Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. J. Natl Cancer Inst.109(12), 1–9 (2017).
   Google Scholar
• Morrison GJ , GoldkornA. Development and application of liquid biopsies in metastatic prostate cancer. Curr. Oncol. Rep.20(4), 35 (2018).
   PubMed Web of Science ®Google Scholar
• Liu W , YinB , WangXet al. Circulating tumor cells in prostate cancer: precision diagnosis and therapy. Oncol. Lett.14(2), 1223–1232 (2017).
   PubMed Web of Science ®Google Scholar
• Heller G , McCormackR , KheohTet al. Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: a comparison with prostate-specific antigen across five randomized Phase III clinical trials. J. Clin. Oncol.36(6), 572–580 (2018).
   PubMedGoogle Scholar
• Bastos DA , AntonarakisES. CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer. Expert Rev. Mol. Diagn.18(2), 155–163 (2018).
   PubMed Web of Science ®Google Scholar
• Scher HI , GrafRP , SchreiberNAet al. Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer. JAMA Oncol.4(9), 1179–1186 (2018).
   PubMed Web of Science ®Google Scholar
• Antonarakis ES , LuC , LuberBet al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J. Clin. Oncol.35(19), 2149–2156 (2017).
   PubMed Web of Science ®Google Scholar
• Millner LM , LinderMW , ValdesRJr. Circulating tumor cells: a review of present methods and the need to identify heterogeneous phenotypes. Ann. Clin. Lab. Sci.43(3), 295–304 (2013).
   PubMed Web of Science ®Google Scholar
• Bernemann C , SchnoellerTJ , LuedekeMet al. Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen deprivation therapy in patients with castration-resistant prostate cancer. Eur. Urol.71(1), 1–3 (2017).
   PubMed Web of Science ®Google Scholar
• Takeuchi T , OkunoY , Hattori-KatoM , ZaitsuM , MikamiK. Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer. Res. Rep. Urol.8, 21–25 (2016).
   PubMed Web of Science ®Google Scholar
• Beltran H , PrandiD , MosqueraJMet al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med.22(3), 298–305 (2016).
   PubMed Web of Science ®Google Scholar
• Corcoran RB , ChabnerBA. Application of cell-free DNA analysis to cancer treatment. N. Engl. J. Med.379(18), 1754–1765 (2018).
   PubMed Web of Science ®Google Scholar
• Ritch E , WyattAW. Predicting therapy response and resistance in metastatic prostate cancer with circulating tumor DNA. Urol. Oncol.36(8), 380–384 (2017).
   PubMed Web of Science ®Google Scholar
• Romanel A , TandefeltDG , ConteducaVet al. Plasma AR and abiraterone-resistant prostate cancer. Sci. Transl. Med.7(312), 312re10 (2015).
   PubMed Web of Science ®Google Scholar
• Azad AA , VolikSV , WyattAWet al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin. Cancer Res.21(10), 2315–2324 (2015).
   PubMed Web of Science ®Google Scholar
• Yegnasubramanian S . Prostate cancer epigenetics and its clinical implications. Asian J. Androl.18(4), 549–558 (2016).
   PubMed Web of Science ®Google Scholar
• Massie CE , MillsIG , LynchAG. The importance of DNA methylation in prostate cancer development. J. Steroid Biochem. Mol. Biol.166, 1–15 (2017).
   PubMed Web of Science ®Google Scholar
• Kron K , LiuL , TrudelDet al. Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer. Clin. Cancer Res.18(10), 2896–2904 (2012).
   PubMed Web of Science ®Google Scholar
• Mahon KL , QuW , DevaneyJet al. Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. Br. J. Cancer111(9), 1802–1809 (2014).
   PubMed Web of Science ®Google Scholar
• Gordevicius J , KrisciunasA , GrootDEet al. Cell-free DNA modification dynamics in abiraterone acetate-treated prostate cancer patients. Clin. Cancer Res.24(14), 3317–3324 (2018).
   PubMed Web of Science ®Google Scholar
• Zhao F , Olkhov-MitselE , vander Kwast Tet al. Urinary DNA methylation biomarkers for noninvasive prediction of aggressive disease in patients with prostate cancer on active surveillance. J. Urol.197(2), 335–341 (2017).
   PubMed Web of Science ®Google Scholar
• Hendriks RJ , DijkstraS , SmitFPet al. Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients. Prostate.78(5), 336–342 (2018).
   PubMed Web of Science ®Google Scholar
• Beltran H , RomanelA , ConteducaVet al. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. J. Clin. Invest.130(4), 1653–1688 (2020).
   PubMed Web of Science ®Google Scholar
• Shen SY , SinghaniaR , FehringerGet al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature563(7732), 579–583 (2018).
   PubMed Web of Science ®Google Scholar
• Ramachandran P , PalidworGA , PorterCJ , PerkinsTJ. MaSC: mappability-sensitive cross-correlation for estimating mean fragment length of single-end short-read sequencing data. Bioinformatics29(4), 444–450 (2013).
   PubMed Web of Science ®Google Scholar
• Kamdar SN , HoLT , KronKJet al. Dynamic interplay between locus-specific DNA methylation and hydroxymethylation regulates distinct biological pathways in prostate carcinogenesis. Clin. Epigenetics8(32), (2016).
   PubMedGoogle Scholar
• Baylin SB , JonesPA. Epigenetic determinants of cancer. Cold Spring Harb. Perspect. Biol.8(9), (2016).
   PubMed Web of Science ®Google Scholar
• Zeng T , ZhuL , LiaoMet al. Knockdown of PYCR1 inhibits cell proliferation and colony formation via cell cycle arrest and apoptosis in prostate cancer. Med. Oncol.34(2), 27 (2017).
   PubMed Web of Science ®Google Scholar
• Yang F , ZhangY , ResslerSJet al. FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res.73(12), 3716–3724 (2013).
   PubMed Web of Science ®Google Scholar
• Manda KR , TripathiP , HsiACet al. NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence. Oncogene35(25), 3282–3292 (2016).
   PubMed Web of Science ®Google Scholar
• Wang R , ChenX , XuTet al. MiR-326 regulates cell proliferation and migration in lung cancer by targeting phox2a and is regulated by HOTAIR. Am. J. Cancer Res.6(2), 173–186 (2016).
   PubMed Web of Science ®Google Scholar
• Takayama K , SuzukiT , FujimuraTet al. CtBP2 modulates the androgen receptor to promote prostate cancer progression. Cancer Res.74(22), 6542–6553 (2014).
   PubMed Web of Science ®Google Scholar
• Yang YA , ZhaoJC , FongKWet al. FOXA1 potentiates lineage-specific enhancer activation through modulating TET1 expression and function. Nucleic Acids Res.44(17), 8153–8164 (2016).
   PubMed Web of Science ®Google Scholar
• Mall M , KaretaMS , ChandaSet al. Myt1l safeguards neuronal identity by actively repressing many non-neuronal fates. Nature544(7649), 245–249 (2017).
   PubMed Web of Science ®Google Scholar
• Zhu S , XuY , SongMet al. PRDM16 is associated with evasion of apoptosis by prostatic cancer cells according to RNA interference screening. Mol. Med. Rep.14(4), 3357–3361 (2016).
   PubMed Web of Science ®Google Scholar
• Mahon KL , QuW , LinHMet al. Serum free methylated glutathione S-transferase 1 DNA levels, survival and response to docetaxel in metastatic, castration-resistant prostate cancer: post hoc analyses of data from a Phase III trial. Eur. Urol.76(3), 306–312 (2019).
   PubMed Web of Science ®Google Scholar
• Brocks D , AssenovY , MinnerSet al. Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep.8(3), 798–806 (2014).
   PubMed Web of Science ®Google Scholar
• Aryee MJ , LiuW , EngelmannJCet al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci. Transl. Med.5(169), 169ra10 (2013).
   PubMed Web of Science ®Google Scholar
• Friedlander TW , RoyR , TomlinsSAet al. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res.72(3), 616–625 (2012).
   PubMed Web of Science ®Google Scholar
• Huang H , DuT , ZhangYet al. Elevation of SHARPIN protein levels in prostate adenocarcinomas promotes metastasis and impairs patient survivals. Prostate77(7), 718–728 (2017).
   PubMed Web of Science ®Google Scholar
• Simovic I , Castano-RodriguezN , KaakoushNO. OPCML: a promising biomarker and therapeutic avenue. Trends Cancer5(8), 463–466 (2019).
   PubMed Web of Science ®Google Scholar
• Zhang D , ParkD , ZhongYet al. Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer. Nat. Commun.7(10798), (2016).
   Google Scholar
• Hara I , YamashitaS , NishizawaS , KikkawaK , ShimokawaT , KohjimotoY. Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer: protocol for a multicenter randomized Phase III trial. JMIR Res. Protoc.7(7), e11191 (2018).
   PubMedGoogle Scholar